2 results
Approved WMOCompleted
Primary objective: To demonstrate that QVA149 (110/50 *g o.d.) is at least non-inferior to salmeterol/fluticasone (50/500 *g b.i.d.) in terms of rate of COPD exacerbations.Secondary objectives: Superiority in terms of exacerbation rate. Time to…
Approved WMOCompleted
The primary objective of the study is to evaluate the long-term safety and tolerability of baricitinib in patients who have completed a previous baricitinib RA study. Safety and tolerability assessments will include:* Treatment-emergent adverse…